Astria Therapeutics Inc ATXS
$12.58 $0.08 (0.64%) 1D
Last Updated: Jan 22, 12:00 AM·NASDAQ
Pricing for US stocks is delayed by 24 hours
ATXS Shariah Compliance
Screening Methodology: AAOIFI
As of August 2026, Astria Therapeutics Inc is classified as not halal.
NOT HALAL
Report Source: undefined Quarter Report
Astria Therapeutics Inc. Stock Analysis ATXS
United States Health Care Small Cap Astria Therapeutics, Inc. engages in the discovery, development, and commercialization of novel therapeutics. The company is headquartered in Boston, Massachusetts and currently employs 78 full-time employees. The company went IPO on 2015-06-25. Its lead product candidate is Navenibart, a potential monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema (HAE), a rare, autosomal dominant genetic disorder. Its second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in clinical development for the treatment of atopic dermatitis (AD), an immune disorder associated with loss of skin barrier function and itching. The company owns five patent families directed to navenibart. The first patent family is directed to the composition of matter of navenibart and its use in treating various plasma kallikrein associated disorders, including HAE. In the second patent family, it is directed to methods of treating various plasma-kallikrein-associated disorders, including HAE.
Astria Therapeutics Inc (ATXS) Chart
Financial Metrics & Statements of Astria Therapeutics Inc (ATXS)
FAQ's for Astria Therapeutics Inc (ATXS)
- As of August 2026, Astria Therapeutics Inc ATXS is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Astria Therapeutics Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Astria Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Astria Therapeutics Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Astria Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Astria Therapeutics Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for Astria Therapeutics Inc (ATXS)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
